Literature DB >> 2050403

Oral immunization against Helicobacter pylori.

S J Czinn1, J G Nedrud.   

Abstract

Helicobacter pylori, which has been associated with gastritis and duodenal ulcers, commonly chronically infects adults. Eradication of this microorganism, which is difficult to achieve, results in normalization of gastritis and marked reduction in the relapse rate of duodenal ulcers. Since eradication is difficult to achieve, prevention of initial colonization of the gastrointestinal tract may be a viable alternative for abrogation of H. pylori-associated gastroduodenal disease. To test the feasibility of this approach, mice and ferrets were orally immunized with killed H. pylori. Immunization induced immunoglobulin A and G anti-H. pylori antibodies in both gastrointestinal secretions and sera of mice. These responses were enhanced when cholera toxin was included in the immunization protocol as a mucosal adjuvant. In ferrets, addition of cholera toxin resulted in significant enhancement of anti-H. pylori antibody levels in sera and intestines. Thus, oral immunization with killed H. pylori may be feasible approach to protect hosts from this infection and the accompanying gastroduodenal disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050403      PMCID: PMC258018          DOI: 10.1128/iai.59.7.2359-2363.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Combined oral/nasal immunization protects mice from Sendai virus infection.

Authors:  J G Nedrud; X P Liang; N Hague; M E Lamm
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

2.  [Search for the best procedure for Campylobacter eradication. Results of long-term studies are still unavailable].

Authors:  G Börsch
Journal:  Fortschr Med       Date:  1989-07-30

Review 3.  Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.

Authors:  J Mestecky; J R McGhee
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

4.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

5.  Serum IgG antibody to the outer membrane proteins of Campylobacter pylori in children with gastroduodenal disease.

Authors:  S Czinn; H Carr; L Sheffler; S Aronoff
Journal:  J Infect Dis       Date:  1989-03       Impact factor: 5.226

Review 6.  Campylobacter pylori: a new pathogen.

Authors:  S J Czinn; W T Speck
Journal:  Adv Pediatr Infect Dis       Date:  1990

7.  The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer.

Authors:  A M Hirschl; E Hentschel; K Schütze; H Nemec; R Pötzi; A Gangl; W Weiss; M Pletschette; G Stanek; M L Rotter
Journal:  Scand J Gastroenterol Suppl       Date:  1988

8.  IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine.

Authors:  A Tagliabue; L Villa; M T De Magistris; M Romano; S Silvestri; D Boraschi; L Nencioni
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

Review 9.  Campylobacter pylori and peptic ulcer disease.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

10.  Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen.

Authors:  C O Elson; W Ealding
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

View more
  28 in total

Review 1.  Helicobacter pylori infection and eradication in paediatric patients.

Authors:  H M Malaty
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

2.  Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model.

Authors:  Rodolfo E Bégué; Halina Sadowska-Krowicka
Journal:  FEMS Immunol Med Microbiol       Date:  2010-08-23

3.  Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants.

Authors:  Rodolfo E Bégué; Alyson Moll
Journal:  Open Vaccine J       Date:  2009-01-01

4.  Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa.

Authors:  H A Haeberle; M Kubin; K B Bamford; R Garofalo; D Y Graham; F El-Zaatari; R Karttunen; S E Crowe; V E Reyes; P B Ernst
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 5.  Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease.

Authors:  Thomas G Blanchard; Steven J Czinn
Journal:  Pediatr Res       Date:  2016-10-04       Impact factor: 3.756

6.  Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production.

Authors:  K Hirota; K Nagata; Y Norose; S Futagami; Y Nakagawa; H Senpuku; M Kobayashi; H Takahashi
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

7.  Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies.

Authors:  G B Pier; G Meluleni; J B Goldberg
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

8.  Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

Authors:  T G Blanchard; N Lycke; S J Czinn; J G Nedrud
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

Review 9.  Diagnostic methods for Helicobacter pylori detection and eradication.

Authors:  A F Goddard; R P H Logan
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

10.  Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice.

Authors:  T G Blanchard; S J Czinn; R Maurer; W D Thomas; G Soman; J G Nedrud
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.